With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

I had no idea this could happen. I wouldn’t have done it,” New Jersey-based former Mounjaro user James Norris, who is now visually impaired, told The Post ...

Vikrant Shrotriya, Novo Nordisk India's Managing Director, addressed concerns over the side effects of Ozempic during a ...

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

You know Ozempic can help with weight loss, but how long can you stay on Ozempic exactly? Unfortunately, there isn’t a solid ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

Vikrant Shrotriya, Corporate Vice President & Managing Director of Novo Nordisk India, during a session on India Today Conclave 2025, said that many celebrities may not want to admit to taking Ozempic ...